| Autor: |
Bryan D Griffin, Eric G. Marcusson, Anne-Claude Gingras, Jun Liu, Feng Yun Yue, Yuko Arita, Maedeh Naghibosadat, Patrick Budylowski, Karen L. Mossman, Queenie Hu, Reuben Samson, Samira Mubareka, Jumai A Abioye, Sang Kyun Ahn, Robert A. Kozak, Mario A. Ostrowski, Michael S. Pollanen, Jordan A. Schwartz, Serena Chau, Lily Yip, Natalia Martin Orozco, Karen Colwill, Giorgi Babuadze, Arinjay Banerjee, Ryan Law, Bhavisha Rathod |
| Rok vydání: |
2021 |
| Předmět: |
|
| Popis: |
Safe and effective vaccines are needed to end the COVID-19 pandemic caused by SARS-CoV-2. Here we report the preclinical development of a lipid nanoparticle (LNP) formulated SARS-CoV-2 mRNA vaccine, PTX-COVID19-B. PTX-COVID19-B was chosen among three candidates after the initial mouse vaccination results showed that it elicited the strongest neutralizing antibody response against SARS-CoV-2. Further tests in mice and hamsters indicated that PTX-COVID19-B induced robust humoral and cellular immune responses and completely protected the vaccinated animals from SARS-CoV-2 infection in the lung. Studies in hamsters also showed that PTX-COVID19-B protected the upper respiratory tract from SARS-CoV-2 infection. Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern (VOCs), including the B.1.1.7, B.1.351 and P.1 lineages. No adverse effects were induced by PTX-COVID19-B in both mice and hamsters. These preclinical results indicate that PTX-COVID19-B is safe and effective. Based on these results, PTX-COVID19-B was authorized by Health Canada to enter clinical trials in December 2020 with a phase 1 clinical trial ongoing (ClinicalTrials.govnumber:NCT04765436).One Sentence SummaryPTX-COVID19-B is a SARS-CoV-2 mRNA vaccine that is highly immunogenic, safe, and effective in preventing SARS-CoV-2 infection in mice and hamsters and is currently being evaluated in human clinical trials. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
